Should I buy or sell NGM Biopharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NGM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGM, but not buy additional shares or sell existing shares. View NGM analyst ratings or view top-rated stocks .

What is NGM Biopharmaceuticals' stock price target for 2024?

4 brokerages have issued twelve-month price targets for NGM Biopharmaceuticals' shares. Their NGM share price targets range from $1.55 to $6.00. On average, they expect the company's share price to reach $3.68 in the next twelve months. This suggests a possible upside of 139.2% from the stock's current price. View analysts price targets for NGM or view top-rated stocks among Wall Street analysts .

How have NGM shares performed in 2024?

NGM Biopharmaceuticals' stock was trading at $0.8590 at the beginning of the year. Since then, NGM shares have increased by 79.3% and is now trading at $1.54. View the best growth stocks for 2024 here .

Are investors shorting NGM Biopharmaceuticals?

NGM Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,390,000 shares, an increase of 42.3% from the March 15th total of 1,680,000 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 4.5% of the shares of the stock are sold short. View NGM Biopharmaceuticals' Short Interest .

When is NGM Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NGM earnings forecast .

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.04. The firm had revenue of $0.17 million for the quarter, compared to analysts' expectations of $2 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com . David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did NGM Biopharmaceuticals IPO?

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free NGM Stock Alerts

$1.54

-0.02 (-1.28%)

(As of 04/5/2024)

Compare

Today's Range: $1.54
▼
$1.57
50-Day Range: $1.47
▼
$1.92
52-Week Range: $0.60
▼
$4.69

Volume: 2.39 million shs
Average Volume: 1.47 million shs
Market Capitalization: $128.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.68

Get NGM Biopharmaceuticals alerts:

NGM Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 139.2% Upside
$3.68 Price Target
Short Interest: Healthy
4.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.54
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.93) to ($0.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

179th out of 911 stocks

Biotechnology Industry

6th out of 33 stocks

3.0

Analyst's Opinion

Consensus Rating
NGM Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
NGM Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.52% of the float of NGM Biopharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
NGM Biopharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NGM Biopharmaceuticals has recently increased by 42.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NGM Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
NGM Biopharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
NGM Biopharmaceuticals has received a 75.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for NGM Biopharmaceuticals is -0.54.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for NGM Biopharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NGM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NGM Biopharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.90% of the stock of NGM Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.74% of the stock of NGM Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NGM Biopharmaceuticals are expected to grow in the coming year, from ($0.93) to ($0.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NGM Biopharmaceuticals is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NGM Biopharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NGM Stock News Headlines

April 16, 2024 | americanbankingnews.com

NGM Biopharmaceuticals (NASDAQ:NGM) Trading Down 1.3%

April 5, 2024 | finanznachrichten.de

NGM Biopharmaceuticals, Inc.: NGM Bio Announces Closing of Tender Offer

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | globenewswire.com

NGM Bio Announces Closing of Tender Offer

March 19, 2024 | globenewswire.com

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

March 13, 2024 | businesswire.com

NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM

March 12, 2024 | bizjournals.com

How a VC and a biotech founder plan to create a new biotech model

March 12, 2024 | msn.com

Oracle, Dollar General upgraded: Wall Street's top analyst calls

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 11, 2024 | globenewswire.com

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024 | msn.com

TD Cowen Downgrades NGM Biopharmaceuticals (NGM)

February 27, 2024 | businesswire.com

February 26, 2024 | bizjournals.com

The Column Group moves forward with plan to take NGM Bio private

February 26, 2024 | finanznachrichten.de

NGM Biopharmaceuticals, Inc.: NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

February 26, 2024 | markets.businessinsider.com

NGM Bio To Be Acquired By Affiliates Of The Column Group, LP

February 26, 2024 | finance.yahoo.com

NGM to go private through deal with investment firm

February 26, 2024 | marketwatch.com

NGM Biopharmaceuticals Shares Drop 20% After $1.55/Shr Buyout Offer

February 26, 2024 | businesswire.com

NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders

February 26, 2024 | marketwatch.com

NGM Biopharmaceuticals Gets Buyout Offer From Column Group Affliates

February 26, 2024 | msn.com

NGM Bio to go private in a $135M deal with Atlas Neon

February 26, 2024 | globenewswire.com

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

February 22, 2024 | finance.yahoo.com

Ascites Market to Observe Stunning Growth During the Study Period (2019–2032) | DelveInsight

February 20, 2024 | finance.yahoo.com

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

February 20, 2024 | globenewswire.com

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

February 13, 2024 | ca.finance.yahoo.com

NGM Biopharmaceuticals, Inc. (NGM)

January 19, 2024 | benzinga.com

Looking Into NGM Biopharmaceuticals's Recent Short Interest

January 17, 2024 | finance.yahoo.com

NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

See More Headlines

Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NGM
CUSIP: N/A
CIK: 1426332
Web: www.ngmbio.com
Phone: (650) 243-5555
Fax: N/A
Employees: 138
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $3.68
High Stock Price Target: $6.00
Low Stock Price Target: $1.55
Potential Upside/Downside: +139.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-142,380,000.00
Net Margins: -3,223.34%
Pretax Margin: -3,223.34%
Return on Equity: -77.85%
Return on Assets: -67.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.79
Quick Ratio: 7.79

Sales & Book Value

Annual Sales: $4.42 million
Price / Sales: 29.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 83,462,000
Free Float: 53,499,000
Market Cap: $128.53 million
Optionable: Optionable
Beta: 1.27

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. William J. Rieflin J.D. (Age 64)
Executive Chairman of the Board of Directors
Comp: $1.1M
Dr. David J. Woodhouse Ph.D. (Age 53)
CEO & Director
Comp: $860.75k
Ms. Valerie L. Pierce J.D. (Age 61)
Senior VP, General Counsel, Secretary & Chief Compliance Officer
Comp: $580.75k
Dr. Hsiao Dee Lieu F.A.C.C. (Age 54)
M.D., Chief Medical Officer & Executive VP
Comp: $625.75k
Jean Frederic Viret Ph.D.
Chief Financial Officer
Ms. Irene Perlich
VP, Corporate Controller & Principal Accounting Officer
Mr. Daniel Kaplan Ph.D.
Chief Scientific Officer
Mahi Saraf
Director of People & Culture
Diana Peng Bockus
Head of Business Development
Arthur Hsu Ph.D.
Senior Director & Head of Biology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NGM Stock Analysis - Frequently Asked Questions

Should I buy or sell NGM Biopharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NGM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGM, but not buy additional shares or sell existing shares.
View NGM analyst ratings or view top-rated stocks.
What is NGM Biopharmaceuticals' stock price target for 2024?: 4 brokerages have issued twelve-month price targets for NGM Biopharmaceuticals' shares. Their NGM share price targets range from $1.55 to $6.00. On average, they expect the company's share price to reach $3.68 in the next twelve months. This suggests a possible upside of 139.2% from the stock's current price.
View analysts price targets for NGM or view top-rated stocks among Wall Street analysts.
How have NGM shares performed in 2024?: NGM Biopharmaceuticals' stock was trading at $0.8590 at the beginning of the year. Since then, NGM shares have increased by 79.3% and is now trading at $1.54.
View the best growth stocks for 2024 here.
Are investors shorting NGM Biopharmaceuticals?: NGM Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,390,000 shares, an increase of 42.3% from the March 15th total of 1,680,000 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 4.5% of the shares of the stock are sold short.
View NGM Biopharmaceuticals' Short Interest.
When is NGM Biopharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NGM earnings forecast.

How were NGM Biopharmaceuticals' earnings last quarter?: NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.04. The firm had revenue of $0.17 million for the quarter, compared to analysts' expectations of $2 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.
What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?: 3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did NGM Biopharmaceuticals IPO?: NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.
How do I buy shares of NGM Biopharmaceuticals?: Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NGM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial